STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Nov. 30, 2022

Equity [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended					Nine Months Ended
	November 30,					November 30,
	2022		2021			2022		2021
Cost of revenues	$	3	$	66		$	88	$	82
Research and development		528		726			1,964		2,240
Selling and marketing		737		856			2,046		2,146
General and administrative		762		1,655			4,088		4,061
Other non-operating expense		-		(151	)		-		32
	$	2,030	$	3,152		$	8,186	$	8,561

Summary of Stock Option Activity

Changes in our outstanding stock options during the nine months ended November 30, 2022 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price			Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2022		664		$	16.38			5.4
Granted		—			—
Exercised		—			—
Forfeited or expired		(14	)		(11.11	)
Outstanding at November 30, 2022		650		$	16.49			4.6	$	-
Exercisable at November 30, 2022		577		$	15.94			4.5	$	-

Summary of Restricted Stock Shares (RSU's), and Performance Stock Units (PSU's) Activity

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the nine months ended November 30, 2022 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 28, 2022		2,940		$	10.39
Granted		2,272			4.64
Vested		(939	)		11.21		356
Forfeited		(634	)		8.40
Outstanding at November 30, 2022		3,639		$	6.95